London: The News
London: The News
RSS Feed: London: The News - Latest NewsFollow the latest London news here

Micro Focus FY Pre-Tax Profit Up, Revenues Down

LONDON (dpa-AFX) - Software product group Micro Focus International plc (MCRO.L, MCFUF.PK) posted an increase in its pre-tax profit for the full year, reflecting lower costs, despite a decrease in...
Reported by FinanzNachrichten.de 11 minutes ago
 
FinanzNachrichten.de
14 minutes ago

Berkeley Annual Profit Climbs

LONDON (dpa-AFX) - The Berkeley Group Holdings Plc's (BKG.L) full-year pre-tax profit advanced 26.0% year-on-year to 270.7 million pounds, from 214.8 million pounds, with profit after tax growing ...

FinanzNachrichten.de
20 minutes ago

AstraZeneca: Onglyza Fails To Meet Primary Efficacy Objective Of Superiority

LONDON (dpa-AFX) - Anglo-Swedish drug maker AstraZeneca Plc. (AZN, AZN.L) and Bristol-Myers Squibb Co. (BMY) announced top-line results of the Phase IV SAVOR-TIMI-53, or Saxagliptin Assessment of ...

This is
25 minutes ago

Iconic pier available to rent for £80,000 a year

This is Grimsby -- THE pier is up for rent at just £80,000 a year – and is proving tempting to potential tenants. Owner Bryn Ilsley wants to lease out the iconic building rather than sell it,..

DailyFinance
29 minutes ago

Guidewire Software Announces Addition of Affecto to PartnerConnect Program

Filed under: Investing *Guidewire Software Announces Addition of Affecto to PartnerConnect Program* Affecto to support Property/Casualty Insurance customers implementing Guidewire..

Irish Times
32 minutes ago

Green Property sells London development to China for £90m

AIB retained interest in One Nine Elms development following sale to Green in 2008

guardian.co.uk
32 minutes ago

UK newspapers' print ad revenue 'to shrink by £400m by the end of 2014'

Group M forecasts digital media will help drive rise in overall UK ad spend – but regional press in particular will suffer Almost £400m in print advertising is forecast to be lost from the UK..

Reuters India
35 minutes ago

AstraZeneca, Bristol diabetes drug fails to show heart benefit

LONDON (Reuters) - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study.

» more London headlines »
Twitter Latest London Tweets
There don't appear to be any related tweets.
Be the first to tweet the news and watch it appear here!
Tell others about this site: FacebookFacebook  EmailE-mail  TwitterTwitter  MixxMixx  StumbleUponStumbleUpon  FriendFeedFriendFeed
 Page 1 >>
© 2013 London: The News / londonthenews.com. All Rights Reserved.  |  Home Page  |  RSS Feed  |  Contact us  |  Bookmark